Moleculin Biotech is trading 5.57% down now at $0.73 after investors reacted to a Nasdaq delisting determination disclosed on September 18, 2026.
- The company failed to maintain Nasdaq’s $1.00 minimum bid price for 30 consecutive business days.
- Nasdaq said it was ineligible for the usual 180-day compliance period because of a recent reverse split.
- Moleculin plans to request a hearing, which would temporarily stay suspension or delisting.